Kwality Pharmaceuticals Ltd — Important, 18-08-2025: Company Update

Kwality Pharmaceuticals has secured product registration for Bleomycin 15 IU in Mexico, an anti-cancer medicine effective in treating Hodgkin’s lymphoma, testicular cancer, and squamous cell carcinomas. This approval significantly strengthens the company's expansion into regulated international markets, underscoring its commitment to global oncology product delivery. The company anticipates a business potential of approximately 0.83 Cr in the first year, with supplies projected to begin before the close of Q2FY26. This development broadens the company's market reach and offers new growth avenues for shareholders.